FOLH1 and neoplasm: Based on AUC calculations, the tumor-to-blood AUC ratio of [177Lu]Lu-Ibu-PSMA-02 was, however, higher than for [177Lu]Lu-Ibu-PSMA-01, which would certainly be favorable in view of a therapeutic application (Supplementary Materials, Figure S5, Table S4).